Cefotaxime/sulbactam: clinical and pharmacological characteristics
The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some extended spectrum beta-lactamases. This paper rev...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2019-12-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2019/3/cmac-2019-t21-n3-p212/cmac-2019-t21-n3-p212.pdf |